BIOMAT Database Logo BIOMAT Database Logo

Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. 1995

R Petrioli, and M Lorenzi, and A Aquino, and S Marsili, and B Frediani, and V Palazzuoli, and G Marzocca, and G Botta, and F Tani, and A De Martino
Medical Oncology Division, Nuovo Policlinico Le Scotte, University of Siena, Italy.

This randomised clinical trial, involving patients with advanced colorectal cancer, was carried out to compare the effectiveness of accelerated folinic acid (FA) plus 5-fluorouracil (5-FU) with that of the conventional regimen of 5-FU alone. Both regimens were administered with simulataneous supportive care. 185 patients were eligible: 94 were randomly allocated to receive FA 200 mg/m2 i.v. plus 5-FU 400 mg/m2 i.v. on days 1-5 every 3 weeks; and 91 to receive 5-FU 400 mg/m2 i.v. on days 1-5 every 4 weeks. The response rate was 33.3% in the accelerated FA/5-FU and 18.6% in the 5-FU arm (P = 0.045). Median survival was 13.5 months in the FA/5-FU arm and 7.5 months in the 5-FU arm (P = 0.039). Toxicity was mild and slightly more pronounced in the FA/5-FU arm (P = 0.078). This study indicates that, in patients with advanced colorectal cancer, accelerated chemotherapy with FA and 5-FU and simultaneous supportive care is capable of achieving a higher response rate and longer survival than conventional 5-FU alone, without severe toxicity.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

R Petrioli, and M Lorenzi, and A Aquino, and S Marsili, and B Frediani, and V Palazzuoli, and G Marzocca, and G Botta, and F Tani, and A De Martino
High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer.
January 1988, Cancer investigation,
R Petrioli, and M Lorenzi, and A Aquino, and S Marsili, and B Frediani, and V Palazzuoli, and G Marzocca, and G Botta, and F Tani, and A De Martino
Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer.
November 1995, Cancer,
R Petrioli, and M Lorenzi, and A Aquino, and S Marsili, and B Frediani, and V Palazzuoli, and G Marzocca, and G Botta, and F Tani, and A De Martino
Folinic acid plus high-dose 5-fluorouracil with allopurinol protection in the treatment of advanced colorectal carcinoma.
January 1990, European journal of cancer (Oxford, England : 1990),
R Petrioli, and M Lorenzi, and A Aquino, and S Marsili, and B Frediani, and V Palazzuoli, and G Marzocca, and G Botta, and F Tani, and A De Martino
Treatment of advanced colorectal cancer with mitoxantrone, high dose folinic acid and fluorouracil.
October 1991, Tumori,
R Petrioli, and M Lorenzi, and A Aquino, and S Marsili, and B Frediani, and V Palazzuoli, and G Marzocca, and G Botta, and F Tani, and A De Martino
Second-line treatment with high-dose 5-fluorouracil and folinic acid in advanced colorectal cancer refractory to standard-dose 5-fluorouracil treatment.
January 1995, Oncology,
R Petrioli, and M Lorenzi, and A Aquino, and S Marsili, and B Frediani, and V Palazzuoli, and G Marzocca, and G Botta, and F Tani, and A De Martino
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
January 1987, NCI monographs : a publication of the National Cancer Institute,
R Petrioli, and M Lorenzi, and A Aquino, and S Marsili, and B Frediani, and V Palazzuoli, and G Marzocca, and G Botta, and F Tani, and A De Martino
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
May 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Petrioli, and M Lorenzi, and A Aquino, and S Marsili, and B Frediani, and V Palazzuoli, and G Marzocca, and G Botta, and F Tani, and A De Martino
Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer.
January 1988, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
R Petrioli, and M Lorenzi, and A Aquino, and S Marsili, and B Frediani, and V Palazzuoli, and G Marzocca, and G Botta, and F Tani, and A De Martino
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.
September 1988, European journal of cancer & clinical oncology,
R Petrioli, and M Lorenzi, and A Aquino, and S Marsili, and B Frediani, and V Palazzuoli, and G Marzocca, and G Botta, and F Tani, and A De Martino
Treatment of advanced breast cancer with 5-fluorouracil and high-dose folinic acid: preliminary results.
April 1985, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
Copied contents to your clipboard!